Research may pave the way for systemic targeted therapy for patients with pseudomyxoma peritonei

FHS
July 20, 2024
12:19 am

Published in Clinical Cancer Research, results of a preclinical study led by investigators of the Vall d’Hebron Institute of Oncology’s (VHIO) Stem Cells and Cancer Group, headed by Héctor G. Palmer, pave the way for systemic targeted therapy in patients with pseudomyxoma peritonei, a rare form of cancer with very few therapeutic options available.

Does the Mediterranean diet meet nutritional requirements during pregnancy?

Whether adopting a healthy diet, such as the MedDiet, during pregnancy could meet the unique macro- and micronutrient requirements of pregnancy.

September 4, 2023

Rice University chemist wins $1M NIH grant to address cancer health disparities

Rice University chemist Carolyn Nichol has won a competitive Science Education Partnership Award (SEPA) from the National Institutes of Health to address race-based cancer health

August 10, 2023

Daiichi Sankyo secures FDA approval for Vanflyta as AML treatment – Pharmaceutical Technology

The FDA opposed Vanflyta’s approval in 2019, citing concerns that the benefits of the drug’s efficacy did not justify the associated safety risks for AML

August 9, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.